Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

Ondansetron followed by placebo

Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.

DRUG

Placebo followed by Ondansetron

Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.

Trial Locations (1)

80220

Denver VAMC, Denver

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Colorado, Denver

OTHER

NCT00149734 - Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia | Biotech Hunter | Biotech Hunter